Lipella Pharmaceuticals Inc. (LIPO) stock
LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $2.27KP/E –Yield –
Lipella Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Lipella Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2025 was $3.57M, up 18.7% year over year. For fiscal 2024 it was $3.61M, up 18.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.61M | +18.9% |
| FY2023 | Dec 31, 2023 | $3.04M | +19.3% |
| FY2022 | Dec 31, 2022 | $2.55M | +74.9% |
| FY2021 | Dec 31, 2021 | $1.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | $720.97K | -31.1% |
| Q2 FY2025 | Jun 30, 2025 | $791.58K | +19.7% |
| Q1 FY2025 | Mar 31, 2025 | $993.48K | +17.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.06M | +133.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.05M | +25.6% |
| Q2 FY2024 | Jun 30, 2024 | $661.56K | -37.4% |
| Q1 FY2024 | Mar 31, 2024 | $842.60K | +21.5% |
| Q4 FY2023 | Dec 31, 2023 | $454.20K | -5.0% |
| Q3 FY2023 | Sep 30, 2023 | $833.26K | +28.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.06M | +42.4% |
| Q1 FY2023 | Mar 31, 2023 | $693.73K | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $478.10K | – |
| Q3 FY2022 | Sep 30, 2022 | $650.95K | – |
| Q2 FY2022 | Jun 30, 2022 | $742.66K | – |
| Q1 FY2022 | Mar 31, 2022 | $675.96K | – |
See a number that looks wrong?